Takeda Pharmaceutical applied in Japan for the psoriasis drug zasocitinib, while Shionogi announced a licensing agreement for cefiderocol in Singapore and Malaysia. Sawai Group Holdings revised down its earnings forecast for the fiscal year ending March, Toho Holdings invested in Oyster Therapeutics, Kissei Pharmaceutical obtained approval for an expanded indication in Taiwan, and Kringle Pharma and Maruishi strengthened their capital relationship.
On 11 November, Takeda Pharmaceutical announced the Japanese application for zasocitinib, a TYK2 inhibitor. The application is based on Phase 3 clinical trial results in patients with moderate to severe plaque psoriasis, pustular psoriasis and psoriatic erythroderma. The application has also been accepted in the United States, where the review target is early 2027.
Shionogi entered into a licensing agreement with Singapore-based Link Healthcare Singapore covering the development and sale of cefiderocol in Singapore and Malaysia. Shionogi will receive consideration related to development and supply, and has previously entered into related agreements within the same group.
Sawai Group Holdings revised its earnings forecast for the fiscal year ending March 2027, projecting revenue of ¥212.7 billion, operating profit of ¥22.9 billion, profit before tax of ¥20.9 billion and net income of ¥13.7 billion. Sales of new products are expected to increase, while lower demand for existing products and higher raw material costs are expected to have an impact.
Toho Holdings announced an investment in UK-based Oyster Therapeutics through its corporate venture capital arm. The target company is developing next-generation TPDs for neurodegenerative diseases and is currently developing an oral TPD targeting tau protein.
Kissei Pharmaceutical obtained approval in Taiwan for an expanded indication of its GnRH antagonist Yselty. The approval was obtained by its licensee, Taiwan-based Synmosa Biopharma.
Kringle Pharma and Maruishi Pharmaceutical agreed to strengthen their capital relationship, with Maruishi subscribing to ¥300 million in Kringle's third-party allotment of new shares. The companies will deepen their collaboration in the sale and promotion of acute spinal cord injury and vocal fold scar treatments.